Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study for Study ALT-103-201: One-year Follow-up for the 1×10(11th) vp NasoVAX Group

NCT03760549 is registered in ClinicalTrials.gov with Altimmune, Inc. as lead sponsor.

NCT NCT03760549
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03760549 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study for Study ALT-103-201: One-year Follow-up for the 1×10(11th) vp NasoVAX Group
Lead sponsor
Altimmune, Inc.
Phase
Observational
Overall status
Completed
Start date
January 21, 2019
Completion date
February 18, 2019
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza